Evidence map›Paper›PMID 39283549›Full record

ArticleClinical rheumatology2024

Disease activity score for still's disease.

Karima Daghor-Abbaci, Nazim Laraba, Chafia Dahou-Makhloufi, Farida Mechid, Nadia Ait-Hamadouche, Mohamed Makrelouf, Amel Otmane, Fifi Otmani, Nourredine Smail, Malika Boucelma and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Karima Daghor-AbbaciInternal Medicine Department, Faculty of Medicine, University of Algiers 1, Bab El Oued University Hospital Center, Said Touati Street, 16000, Bab El Oued, Algiers, Algeria. abbacidaghor@gmail.com.ORCID http://orcid.org/0000-0002-5669-5759
Nazim LarabaInternal Medicine Department, Faculty of Medicine, University of Algiers 1, Bab El Oued University Hospital Center, Said Touati Street, 16000, Bab El Oued, Algiers, Algeria.
Chafia Dahou-MakhloufiRheumatology Department, Bab El Oued University Hospital Center,, Algiers, Algeria.
Farida MechidRheumatology Department, Bab El Oued University Hospital Center,, Algiers, Algeria.
Nadia Ait-HamadoucheDepartment of Epidemiology, Bab El Oued University Hospital Center, Bab El Oued City, Algiers, Algeria.
Mohamed MakreloufBiochemistry Hemotology and Genetics Laboratory of Research, Faculty of Medicine, University of Algiers 1, Bab El Oued University Hospital Center, Algiers, Algeria.
Amel OtmaneBiochemistry Hemotology and Genetics Laboratory of Research, Faculty of Medicine, University of Algiers 1, Bab El Oued University Hospital Center, Algiers, Algeria.
Fifi OtmaniInternal Medicine Department, Mustapha Bacha University Hospital Center, Algiers, Algeria.
Nourredine SmailDepartment of Epidemiology, Mustapha Bacha University Hospital Center, 1St May City, Algiers, Algeria.
Malika BoucelmaInternal Medicine Department, Kouba University Hospital Center, Kouba City, Algiers, Algeria.
Salima Lefkir-TeffianiRheumatology Department, Benimessous University Hospital Center, Algiers, Algeria.
Bilal BenganaRheumatology Department, Benimessous University Hospital Center, Algiers, Algeria.
Nadia BoukhrisInternal Medicine Department, Ibn Sina University Hospital Center, Annaba City, Algeria.
Samia BoughandjiouaInternal Medicine Department, Ibn Sina University Hospital Center, Annaba City, Algeria.
Baya TaharbouchetInternal Medicine Department, Bouloughine University Hospital Center, Algiers, Algeria.
Soraya AyoubInternal Medicine Department, Benimessous University Hospital Center, Benimessous City, Algiers, Algeria.
Nadia OumniaInternal Medicine Department, Zmirli University Hospital Center, Algiers, Algeria.
Chafika HaouichetRheumatology Department, Douera University Hospital Center, Blida City, Algeria.
Fella HanniRheumatology Department, Benaknoun University Hospital Center, Algiers, Algeria.
Nacera BenfenatkiInternal Medicine Department, Rouiba University Hospital Center, Algiers, Algeria.
Abdelkrim BerrahInternal Medicine Department, Faculty of Medicine, University of Algiers 1, Bab El Oued University Hospital Center, Said Touati Street, 16000, Bab El Oued, Algiers, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop the Still's Disease Activity Score (SDAS).

methodsWe used data from the prospective adult-onset Still's disease cohort study and evaluated the disease activity. An expert group selected the most frequent, reproducible, and objective variables significantly modified in statistical analysis when comparing patients in the active group and in the remission group. These criteria were weighted to design the Still's Disease Activity Score (SDAS). The Delphi method was used to appreciate the level of disease activity. Total SDAS was calculated for each patient and compared to final consensus experts.

resultsAt the diagnosis, all patients had an active disease (n = 80), while 48 patients were in remission at 6 months. The SDAS criteria were weighted as follows: fever ≥ 38.5 °C (1 point), rash (1 point), joint involvement (arthralgia: 1 point, swollen joints count "SJC": 1-3 SJC: 2 points, ≥ 4 SJC: 3 points), physician global assessment VAS ≥ 5/10 or a raise in physician VAS ≥ 2/10 (3 points), patient VAS ≥ 5 or a raise in patient VAS ≥ 2/10 (1 point), and CRP (> 10 mg/l: 1 point, ≥ 100 mg/l: 2 points). At 6 months, the consensus was achieved for 76 (95%) patients with 40 in remission (0-1 point), 8 in low disease activity (2-3 points), 16 in moderate disease activity (4-7 points), and 12 in severe disease activity (≥ 8 points).

conclusionThe Still's Disease Activity Score is a valid and sensitive assessment of the disease activity and the therapeutic response in Still's disease, despite its heterogeneous manifestations and patterns with systemic and articular forms. Key Points • The Still's Disease Activity Score (SDAS) is a good simple tool to assess the activity of the disease in a stable state for a week. • The SDAS is developed specifically for Still's disease without the need for an application or a calculator to calculate SDAS in routine clinical practice. • SDAS is a composite score classifying the disease activity in remission, low disease activity, moderate disease activity, and severe disease activity despite its heterogeneous patterns (systemic and articular forms). • The SDAS is a valid, reliable, and sensitive score and can be useful to guide the therapeutic strategy in clinical practice and in research.

Indexed as

Severity of Illness IndexStill's Disease, Adult-OnsetAdultAntirheumatic AgentsArthralgiaDelphi TechniqueFemaleHumansMaleMiddle AgedProspective StudiesRemission InductionAntirheumatic AgentsCRPFeverPhysician VASStill’s Disease Activity Score (SDAS)

Identifiers

PMID39283549

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.